Published in J Clin Endocrinol Metab on January 08, 2010
Bone, sweet bone--osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol (2012) 1.73
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol (2010) 1.72
Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res (2011) 1.70
Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab (2014) 1.61
Bone metabolism in obesity and weight loss. Annu Rev Nutr (2012) 1.28
High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care (2013) 1.19
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep (2010) 1.18
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia (2012) 1.08
Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab (2010) 1.05
The many facets of PPARgamma: novel insights for the skeleton. Am J Physiol Endocrinol Metab (2010) 1.04
Interpreting adverse signals in diabetes drug development programs. Diabetes Care (2013) 0.99
A high-fat diet induces bone loss in mice lacking the Alox5 gene. Endocrinology (2011) 0.91
Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail (2014) 0.90
Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep (2015) 0.88
Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 0.87
Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int (2012) 0.87
Risk of fracture with thiazolidinediones: disease or drugs? Calcif Tissue Int (2012) 0.86
Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging (2014) 0.85
Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne) (2013) 0.85
Oxidative stress and heme oxygenase-1 regulated human mesenchymal stem cells differentiation. Int J Hypertens (2012) 0.84
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int (2015) 0.83
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol (2015) 0.83
Safety of Anti-Diabetic Therapies on Bone. Clin Rev Bone Miner Metab (2012) 0.81
Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res (2012) 0.80
Cthrc1 controls adipose tissue formation, body composition, and physical activity. Obesity (Silver Spring) (2015) 0.80
Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration. Bone (2012) 0.79
Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol (2011) 0.78
Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013. Clin Med Insights Endocrinol Diabetes (2016) 0.78
Risk of fractures and diabetes medications: a nationwide cohort study. Osteoporos Int (2016) 0.78
[Diabetes and osteoporosis: pathophysiological interactions and clinical importance for geriatric patients]. Z Gerontol Geriatr (2013) 0.77
Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights Endocrinol Diabetes (2010) 0.77
Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail (2013) 0.77
Type 1 diabetes and osteoporosis: A review of literature. Indian J Endocrinol Metab (2014) 0.77
Treating the elderly diabetic patient: special considerations. Diabetes Metab Syndr Obes (2014) 0.77
Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P T (2012) 0.77
Antidiabetic medications and polypharmacy. Clin Geriatr Med (2014) 0.76
Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option? Wien Klin Wochenschr (2010) 0.76
Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res (2014) 0.75
Update on Safety Issues Related to Antihyperglycemic Therapy. Diabetes Spectr (2014) 0.75
Obesity is a concern for bone health with aging. Nutr Res (2017) 0.75
[Interaction between bone, fat and insulin]. Z Rheumatol (2014) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Thiazolidinediones. N Engl J Med (2004) 9.42
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest (2004) 5.29
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
PPAR-gamma regulates osteoclastogenesis in mice. Nat Med (2007) 3.59
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ (2008) 3.56
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology (2003) 2.84
Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf (2009) 2.67
Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab (2006) 2.34
Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care (2007) 2.16
Thiazolidinediones and fractures in men and women. Arch Intern Med (2009) 1.98
Higher incidence of falls in long-term stroke survivors than in population controls: depressive symptoms predict falls after stroke. Stroke (2002) 1.94
Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care (2001) 1.84
Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology (2004) 1.84
Chronic kidney disease and bone fracture: a growing concern. Kidney Int (2008) 1.76
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int (2004) 1.69
Biphasic fracture risk in diabetes: a population-based study. Bone (2007) 1.68
Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol (2007) 1.67
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol (2004) 1.67
Skeletal consequences of thiazolidinedione therapy. Osteoporos Int (2007) 1.42
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med (2009) 1.40
Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res (2004) 1.33
From the Food and Drug Administration. JAMA (2000) 1.32
Thiazolidinedione-induced skeletal fragility--mechanisms and implications. Diabetes Obes Metab (2008) 1.30
TZDs and Bone: A Review of the Recent Clinical Evidence. PPAR Res (2008) 1.13
Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int (2009) 1.08
Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab (2003) 1.05
A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab (2009) 1.04
Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology (2008) 1.03
Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause (2009) 0.96
Diabetes, TZDs, and Bone: A Review of the Clinical Evidence. PPAR Res (2006) 0.94
Proton pump inhibitors and bone fractures? Am J Gastroenterol (2009) 0.94
Clinical manifestations and current treatment options for diabetic neuropathies. Endocr Pract (2007) 0.92
Women, type 2 diabetes, and fracture risk. Curr Diab Rep (2004) 0.89
A computer assisted photogrammetric analysis of soft tissue changes after orthodontic treatment. Part I: Methodology and reliability. Am J Orthod Dentofacial Orthop (1995) 0.85
Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. Bone (2005) 0.81
Bone seems susceptible to range of drugs. Nat Med (2009) 0.79
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry (2007) 3.78
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Building a virtual cancer research organization. J Natl Cancer Inst Monogr (2005) 3.60
Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care (2004) 3.31
Genetic ancestry in lung-function predictions. N Engl J Med (2010) 3.30
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 2.95
Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol (2004) 2.44
When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation (2008) 2.37
A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care (2006) 2.22
The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry (2009) 2.13
Man's best friend? The effect of pet ownership on house dust microbial communities. J Allergy Clin Immunol (2010) 2.06
Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry (2010) 1.89
Patient-physician colorectal cancer screening discussions and screening use. Am J Prev Med (2006) 1.87
Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry (2009) 1.85
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol (2012) 1.76
Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol (2007) 1.67
The services for children and adolescents-parent interview: development and performance characteristics. J Am Acad Child Adolesc Psychiatry (2004) 1.64
Socioeconomic status and childhood asthma in urban minority youths. The GALA II and SAGE II studies. Am J Respir Crit Care Med (2013) 1.64
An outbreak of travel-associated Legionnaires disease and Pontiac fever: the need for enhanced surveillance of travel-associated legionellosis in the United States. J Infect Dis (2001) 1.59
Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol (2010) 1.57
Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol (2011) 1.56
Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail (2012) 1.55
Improving asthma care through recertification: a cluster randomized trial. Arch Intern Med (2007) 1.54
Further replication studies of the EVE Consortium meta-analysis identifies 2 asthma risk loci in European Americans. J Allergy Clin Immunol (2012) 1.54
AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry (2004) 1.53
The impact of diabetes on employment and work productivity. Diabetes Care (2005) 1.50
Differences in allergic sensitization by self-reported race and genetic ancestry. J Allergy Clin Immunol (2008) 1.47
A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2004) 1.47
Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol (2002) 1.45
Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry (2009) 1.44
Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 1.38
Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology (2007) 1.38
Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids. J Allergy Clin Immunol (2006) 1.36
Reducing the health risks of diabetes: how self-determination theory may help improve medication adherence and quality of life. Diabetes Educ (2009) 1.36
Inconsistencies in patient perceptions and observer ratings of shared decision making: the case of colorectal cancer screening. Patient Educ Couns (2010) 1.35
Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry (2006) 1.34
Dissemination of the Coping Power program: importance of intensity of counselor training. J Consult Clin Psychol (2009) 1.32
Colorectal carcinoma screening procedure use among primary care patients. Cancer (2005) 1.29
Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia (2006) 1.28
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord (2008) 1.27
Factors contributing to the racial differences in prostate cancer mortality. BJU Int (2005) 1.26
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry (2005) 1.26
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry (2009) 1.24
Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach. Pharm Stat (2014) 1.24
Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. Ann Allergy Asthma Immunol (2008) 1.23
Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). Circulation (2010) 1.22
Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr (2002) 1.19
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord (2008) 1.18
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf (2009) 1.18
Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry (2012) 1.18
Evaluation of a web-based asthma management intervention program for urban teenagers: reaching the hard to reach. J Adolesc Health (2012) 1.18
A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol (2010) 1.16
Recruiting older African American men to a cancer screening trial (the AAMEN Project). Gerontologist (2003) 1.16
Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther (2004) 1.16
Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J (2008) 1.15
A comparison of hand washing techniques to remove Escherichia coli and caliciviruses under natural or artificial fingernails. J Food Prot (2003) 1.15
An african-specific functional polymorphism in KCNMB1 shows sex-specific association with asthma severity. Hum Mol Genet (2008) 1.15
Prioritization of evidence-based preventive health services during periodic health examinations. Am J Prev Med (2012) 1.14
Adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother (2007) 1.12
Recruitment of African Americans with type 2 diabetes to a randomized controlled trial using three sources. Ethn Health (2002) 1.12
Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J (2006) 1.12
Antibiotic exposure in early infancy and risk for childhood atopy. J Allergy Clin Immunol (2005) 1.12
Comparing methods for identifying patients with heart failure using electronic data sources. BMC Health Serv Res (2009) 1.12
Onset of alcohol or substance use disorders following treatment for adolescent depression. J Consult Clin Psychol (2012) 1.10
Negative emotions and alcohol use initiation in high-risk boys: the moderating effect of good inhibitory control. J Abnorm Child Psychol (2004) 1.10
The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord (2014) 1.08
Environmental epidemiology of pediatric asthma and allergy. Epidemiol Rev (2002) 1.08
Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma. Am J Respir Crit Care Med (2008) 1.07
Early complementary feeding and risk of food sensitization in a birth cohort. J Allergy Clin Immunol (2011) 1.05
Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma. J Allergy Clin Immunol (2006) 1.05
Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology (2006) 1.05
Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem Pharmacol (2004) 1.04
Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol (2008) 1.04